Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will engage in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on January 10, 2022, at 2:15 p.m. ET. The event will be accessible via a live audio webcast for investors, analysts, media, and the public. As a global healthcare company focusing on women's health, Organon offers over 60 products and aims to expand its biosimilars business while collaborating with biopharmaceutical innovators. For more details, visit here.
Merck (NYSE: MRK) received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA, recommending its approval as an adjuvant treatment for adults with renal cell carcinoma (RCC) at risk of recurrence post-nephrectomy. This decision is based on the Phase 3 KEYNOTE-564 trial, which showed a 32% improvement in disease-free survival compared to placebo. The final decision by the European Commission is expected in Q1 2022. This advancement in treatment options aims to address a significant gap for RCC patients following nephrectomy.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics announced that the MOVe-OUT trial results for molnupiravir, an oral antiviral for COVID-19, were published in the New England Journal of Medicine. The Phase 3 trial showed a 50% reduction in hospitalization or death for high-risk, unvaccinated adults. The drug has gained authorization in the UK and is under review by the FDA and EMA. The study involved a diverse population across 20 countries and indicated molnupiravir's effectiveness against COVID-19 variants, including Omicron.
Merck (NYSE: MRK) has received approval from the European Commission for VAXNEUVANCE™, a Pneumococcal 15-valent Conjugate Vaccine, which will be marketed in all 27 EU Member States, as well as Iceland, Norway, and Lichtenstein. This vaccine targets invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 and older. The approval is based on positive results from seven clinical studies involving 7,438 participants, showing that VAXNEUVANCE achieved immune responses superior to the previously available 13-valent vaccine.
Merck has received approval from the European Commission for its pneumococcal vaccine, VAXNEUVANCE, aimed at preventing invasive disease and pneumonia caused by Streptococcus pneumoniae in adults 18 and older. This approval follows a positive opinion from the European Medicines Agency based on data from clinical studies involving 7,438 participants. VAXNEUVANCE is now authorized for marketing in all 27 EU member states, as well as in Iceland, Norway, and Lichtenstein, offering a new immunization option for patients in these regions.
Merck (NYSE: MRK) announced that the FDA has placed clinical holds on several investigational new drug applications for islatravir (MK-8591) due to decreases in lymphocyte and CD4+ T-cell counts observed during clinical studies. The holds affect oral and injectable formulations for HIV-1 treatment and prevention, halting further dosing and enrollment in several trials. Affected studies include Phase 3 trials for oral islatravir as pre-exposure prophylaxis (PrEP) in high-risk populations. Merck remains committed to addressing unmet needs in HIV care.
Organon (NYSE: OGN) has completed its acquisition of Forendo Pharma, enhancing its women's health pipeline with novel treatments for endometriosis and polycystic ovarian syndrome (PCOS). The transaction includes a $75 million upfront payment and potential total consideration of up to $954 million based on development and commercial milestones. Forendo's lead candidate, FOR-6219, is entering Phase 2 clinical trials and aims to offer a long-term treatment option for endometriosis, addressing significant unmet needs in women's health.
Summary not available.
Summary not available.
Merck (NYSE: MRK) has announced an additional $150 million commitment to its Merck for Mothers initiative, aiming to enhance maternal health globally. This investment builds upon a previous $500 million commitment made in 2011, targeting to support programs that will reach 25 million women by 2025, up from 13.1 million to date. The funding is crucial as the COVID-19 pandemic has hindered maternal care, particularly in high-need regions like India, Nigeria, and Kenya. A minimum of $15 million will also support initiatives addressing maternal health disparities in the U.S.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
